Purpose This study aims to analyze the utilization and effectiveness of injectable spasticity medications by the physiatry team at a referral-based tertiary cancer center. Methods A retrospective review and analysis of patient and injection characteristics were obtained from patients who had received onabotulinum toxin or phenol nerve block injections from December 1, 2007 through January 31, 2012. Out of 3,724 physiatry consultations during this period, 20 (less than 1 %) different cancer patients received a total of 54 total procedures. Results The majority of patients (17/20, 85 %) had a positive response to the injection. A positive response to the injection was defined by: (1) if the patient qualified to receive and was given another injection or (2) if there is a record of improvement if they did not receive another injection. A total of ten of 20 (50 %) patients received only one injection. Of these, seven of ten (70 %) reported a positive response to the injected agent. Those with only one injection tended to live farther away and die sooner. Four of 54 (7 %) injection procedures resulted in undesirable reported side effects (two for phenol, two for botulinum toxin). Nine of 54 (17 %) procedures occurred while the patients were on a chemotherapy protocol. All patients were injected at least 1 year out from initial diagnosis.
Introduction
Onabotulinum toxin is approved by the Federal Drug Administration for a variety of diagnoses including upper limb spasticity and cervical dystonia. Multiple studies have shown the efficacy of botulinum toxin in different populations with central nervous system (CNS) injury including spinal cord injury, stroke, traumatic brain injury, and cerebral palsy [1] [2] [3] [4] . Research on the use of phenol nerve blocks for spasticity management dates back decades [5] [6] [7] .
Cancer patients can suffer from spasticity and dystonia due to the disease itself and its treatments. The treatment of spasticity and dystonia can include therapy, exercises, splints/casts, oral spasticity medications, botulinum toxin injections, neurolytic agents (e.g., phenol) and intrathecal baclofen pumps.
Few papers have focused on the use of botulinum toxin and nerve blocks in the cancer population. Botulinum toxin has been studied for radiation fibrosis syndrome, pain, hypersalivation, and trismus [8] [9] [10] [11] [12] . There are several studies on the use of botulinum toxin use for chest skeletal muscle spasms in post-mastectomy patients [13] [14] [15] [16] . There are no other publications on the use of injectable treatments in a cancer population for spasticity and dystonia. This may be due to the limited availability and underutilization of physiatry services. Unfortunately, physical medicine and rehabilitation is unavailable in many cancer centers [17] . Therefore, spasticity and dystonia injectable interventions are often also unavailable. When available, cancer rehabilitation is often underutilized due to a lack of awareness of its role and potential benefits [18] [19] [20] [21] . The purpose of this study is to evaluate the utilization and results of these spasticity management injections in a cancer population.
Methods

Subjects
A retrospective review of medical records revealed 22 patients who had received onabotulinum toxin or phenol nerve block injections by the physiatry clinic at a referral based tertiary cancer center from December 1, 2007 through January 31, 2012. Of those 22 patients, 20 patients had a history of cancer. A total of 54 total spasticity procedures were performed on these cancer patients.
Procedure
Approval for this study was obtained from the institutional review board. Data were collected by experienced clinicians from therapy notes and medical records. Information obtained included demographic information (date of birth, date of diagnosis, date of death, gender, race, gender, insurance type, distance from hospital), blood counts, primary cancer, cause of spasticity/hypertonia, indication for injection, guidance methods utilized, dosage of agent used, adverse reactions reported, date of last craniotomy, date of last radiation, date of last chemotherapy agent, and prior use of oral muscle relaxants. Information regarding the effectiveness of the injected agent and reasons for not receiving a repeat injection were also obtained. The distance of the patient's residence from the hospital was calculated using Google Maps.
A positive response to an injection was defined by: (1) if the patient qualified to receive and was given another injection or (2) if they did not receive another injection, it was stated in the medical record that an improvement in tone was observed.
Results
Demographics for the patients are listed in Table 1 . The median days since diagnosis is quite long at 1,447 days (range, 377-6,279). All patients were at least 1 year out from their diagnosis. Table 2 presents the characteristics of the patients' medical histories. Most patients had never been on an oral spasticity agent. Five injections occurred while a patient was on oral spasticity medication. The most common cause of spasticity was due to the brain tumor and its resection. Table 3 presents the procedure characteristics. The only type of botulinum toxin used was onabotulinum toxin. Most patients received onabotulinum toxin without phenol. Some patients were actively on chemotherapy at the time of their injection. A total of 43/54 procedures occurred while the patient was already in physical and occupational therapy or immediately enrolled in it after the injection. There were 50/54 procedures that occurred in the outpatient clinic. Table 4 outlines the differences between patients who received multiple injections and those that received only one. It is of note that the majority of these patients did have a positive effect from their spasticity injections (seven of ten). Those who received only one injection are notable for two major differences. Many patients only received one injection because they died soon after and/or before they were due for another injection. Many of these patients also lived farther away than their multiple-injection counterparts. There were no statistically significant differences between the single-injection group and the multipleinjection group with regard to mortality or distance from MDACC (p-values 0.650 and 0.326, respectively). Given the large difference in median distance, the lack of statistical significance is likely due to the small sample size. There was a marginally statistically significant difference in overall survival between the single-and multiple-injection groups (p-value00.0589).
There were nine of 54 injections that occurred while the patients were actively on chemotherapy. The majority of them were on oral chemotherapy (temazolamide). One injection occurred between intravenous lymphoma chemotherapy dosages. One may be concerned regarding infection risk (especially if leukopenic) and/or bleeding risk (if the patient is thrombocytopenic). For our patients, platelet counts within 1 month of injection were as low as 69,000 per microliter. White blood cell counts were as low as 1,900 per microliter. If the patient was on chemotherapy at the time of planned injection, the primary oncologist was asked before proceeding. There were some cases where the oncologist preferred for us to hold off on the injection (which we honored). However, the answers were variable depending on the oncologist. There are no formal guidelines with respect to the use of botulinum toxin injections and concomitant chemotherapy or minimum blood cell levels. None of the patients injected while on chemotherapy experienced any botulinum toxin/phenol-related complications.
Discussion
The purpose of this study was to analyze the utilization and effectiveness of injectable spasticity medications at our referral-based tertiary cancer center. While this study portrays experiences only at our institution, this descriptive study illustrates the experiences of managing a cancer population with spasticity using injectable agents. The treatment of these patients' spasticity was fairly standard. Many patients had received oral spasticity agents in the past and most were also receiving physical and occupational therapy. The results of this study suggest that spasticity management injections are effective when given to these patients. A total of 17/20 (85 %) patients had a positive response. Half of the patients (ten of 20, 50 %) received multiple injections, strongly suggesting that the first injection was effective. Most patients who only received one injection also had reports of improvement in their tone (seven of ten, 70 %). Response to the injection is dependent upon a number of factors including the skill of the injector, guidance methods used, and using adequate dosages of botulinum toxin. Randomized placebo-controlled trials with spasticity measurements and multiple injectors are needed to better define its effectiveness in this population. The majority of patients had few reported adverse effects to the injectable agent. Bakheit et al., in a randomized, double-blind, placebo-controlled trial of botulinum toxin type A in noncancer stroke patients with spasticity, reported adverse reactions in 16/27 patients. This, however, was not higher than placebo (20/32) [2] . Excessive muscle weakness in the injected area has been reported as high as 6-11 % in noncancer cervical dystonia patients [22] . Neuropathic sensory discomfort has been reported in 9 % of lower extremity nerve block non-cancer patients [23] . Only eight of 20 of our patients had ever taken oral spasticity agents. Oral spasticity medications are less successful in treating spasticity in cerebral injury than in spinal cord injury [24, 25] . This is primarily due to the significant sedating effects of these medications in patients who already have cerebral compromise. Most of our patients had a brain injury and most never received a trial of oral spasticity agents. From our 607-bed cancer hospital, having only 20 different cancer patients injected and 54 total injection procedures over a 4-year period seems quite low. During that same time period, our physiatry service received 3,724 consultations. This may be explained by a number of factors. First, we have anecdotally observed that the incidence of spasticity in our cancer population is quite low especially in comparison to our colleagues who primarily treat other CNS injury etiologies. It has been reported that between 19 and 39 % of stroke [26, 27] , between 40 and 65 % of spinal cord injuries [28, 29] , and 34 % of traumatic brain injury survivors suffer from spasticity [30, 31] . A total of 3,724 physical medicine and rehabilitation (PM&R) consultation cases (921 from neuro-oncology and neurosurgery) were seen during that time period. Less than 1 % of all patients referred to PM&R received an injection. All of the patients injected had had cancer initially diagnosed for over a year. This is also interesting considering that the median lifespan for glioblastoma multiforme (the most commonly encountered primary brain tumor in adults) is 15 months [32] . By the time a year has transpired, the majority of high-grade astrocytoma patients have completed radiation therapy or are actively on some type of chemotherapy, and many have already died. Six of 19 (32 %) of our patients had a diagnosis of glioblastoma multiforme. Due to the time it takes to develop spasticity, CNS tumor patients should receive regular follow-up by a physical medicine and rehabilitation specialist. On average, we have 30-40 high-grade astrocytoma patients admitted to our inpatient rehabilitation unit each year as well as more on a consultation basis. In terms of spinal cord injury, we had no patients with a proven spinal cord injury.
Second, inadequate utilization by oncologic providers of physiatry services is likely a factor. Other research has found physiatry services to be underutilized for cancer patients [18] [19] [20] [21] . This could be due to poor awareness regarding the availability of physiatry treatments. The cancer and its treatment also get the focus from referring oncologists. Consequently, less attention or importance is given to other symptoms such as spasticity. At our institution, attempts have been made to educate referring services regarding the availability of injectable spasticity medications by physiatry and to remind them to identify spasticity when present. As cancer survivor numbers continue to grow, more attention should be placed on residual symptoms such as spasticity.
Finally, another likely contributor is the large proportion of patients who only receive one injection (ten of 20, 50 %). Table 4 sheds some light on the possible reasons for this. Many of our patients come from long distances to seek care at our institution primarily for management of their cancer, not for rehabilitation needs. We suspect that many patients with spasticity are treated by local clinicians. Another issue is the mortality that we encounter working in a tertiary cancer center. Some of the patients died by the time they were due for more injections.
Many of the limitations of this study are due to its design. This is a retrospective study meant to familiarize the reader with what we have experienced at our institution. There is little published research regarding spasticity 
Conclusion
Physiatry can offer effective treatments that are not otherwise available at many cancer centers, including phenol and botulinum toxin injections. Despite a small percentage of patients receiving these injections, overall they appear to be safe and effective. These injections are useful and should be available to cancer patients. When available, cancer specialists should be educated on the potential benefits of these medications for their patients.
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